Finanzwire Finanzwire
Basculer en Français
9629 Companies
191458 Keywords
122917 Articles
102032 Press releases
Headlines Articles Press releases Clairvoyant Therapeutics Remove
  1. Home
  2. Companies
  3. Clairvoyant Therapeutics
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/03/2024 at 14:05, 1 year 9 months ago

    Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder

    Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder Regulatory Pathway
  • PRESS RELEASE

    published on 04/03/2024 at 14:00, 1 year 9 months ago

    Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

    Clairvoyant Therapeutics aims to commercialize psilocybin treatment for alcohol use disorder by 2025. Company's trial progressing well, expecting results in 2024 & financing round underway
    Commercialization Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder
    Logo of Clairvoyant Therapeutics
  • PRESS RELEASE

    published on 11/29/2023 at 13:00, 2 years 1 month ago

    Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

    Logo of Clairvoyant Therapeutics
  • PRESS RELEASE

    published on 03/20/2023 at 12:00, 2 years 9 months ago

    First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder

    Logo of Clairvoyant Therapeutics
Accesswire
  • Published on 01/10/2026 at 05:10, 1 day 19 hours ago

    Sekur Private Data Ltd. Announces Non-Brokered Private Placement

  • Published on 01/10/2026 at 00:45, 1 day 23 hours ago

    Digi Power X Announces Entry into Settlement Agreement

  • Published on 01/09/2026 at 23:30, 2 days ago

    Sun Peak Metals Grants Stock Options

  • Published on 01/09/2026 at 23:30, 2 days ago

    Matador Technologies Announces Grant of Restricted Share Units to Management Team

  • Published on 01/09/2026 at 23:10, 2 days 1 hour ago

    Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction

View all ACCESSWIRE
EQS Group
  • Published on 01/11/2026 at 22:20, 1 hour 51 minutes ago

    Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

  • Published on 01/10/2026 at 21:25, 1 day 2 hours ago

    CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh

  • Published on 01/10/2026 at 13:05, 1 day 11 hours ago

    SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation

  • Published on 01/09/2026 at 21:55, 2 days 2 hours ago

    Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)

  • Published on 01/09/2026 at 18:36, 2 days 5 hours ago

    Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS
Les Echos
  • Published on 01/09/2026 at 18:30, 2 days 5 hours ago

    H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm

  • Published on 01/09/2026 at 17:45, 2 days 6 hours ago

    January 2026

  • Published on 01/09/2026 at 17:45, 2 days 6 hours ago

    MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

  • Published on 01/09/2026 at 17:42, 2 days 6 hours ago

    Aéroports de Paris SA - Shares and voting rights as of 31 December 2025

  • Published on 01/08/2026 at 21:00, 3 days 3 hours ago

    Biannual report on SEB S.A.’S liquidity agreement

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy